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The concept that life-threateomg ventricular tachyarrhyth- 
miss could be terminated in closed chest subjects by mcan$ 
ofinternally delivered electrical countershocks. and that this 
maneuver could be performed automatically by an electronic 
device pemtanently implanted in high risk pattent~ to protect 
them from arrhythmic death, goes back to the late 1960s 
(12). Initially. the idea was not well received by critics (3) 
and hardly caotured the lmaeination of either clinicians or 
engineers: In b. only a haidfol of workers became com- 
mitted to its practical imo!emwtadon. It should not be 
surprising, the&re. that tic tmte needed for the solution of 
the multitude of problems inherect in such an endeavor was 
longer than expected @-IO). 
Since the first automatic defibrillator was implanted in a 
human being (IO), the clinical acceptance of internal aura- 
matic defibrillation has been erowine steadiiv. Sieniticantlv 
enough, technologic advan& have kept &with the 
clinical progress. Although the initial model of the device 
only detected and treated ventricular fibrillation, cardiovert- 
ing capabilities were soon added to the design, expanding the 
diarmostic and themoeutic wtential of the svstem to include 
the-broad spectrum of v;ntrtcutar tachy&bythmias. Re- 
ceotly, the first folly hybridized version of the device was 
introduced (VENTAK. Cardiac Pacemakers, Inc.). bcilitat- 
ing the mattufacturing process and assuring the availability 
of pulse generators. Smaller and more advanced models, 
incorporating pacing for :acby- and bmdyarrbythmiar, pro- 
grammability, memory and so forth, have already left the 
drawing b0dI.d and a& about to enter clinical trials. 
So far, >2,5W paiients have been treated with the auto. 
matic implantable cardiovener.defibrillator, also known by 
its acronym AICD. Experience indicates that the device 
oerforms I~C deslgned funcoons ~adsfactorily. that the risks 
wrociated with its USC are moderate and frequentty avoid- 
able and. most importantly, fbat its impact on the wrvivat of 
[be implaniees 1s dramatic indeed. Although the sudden 
death monabty in the types of patients operated on ranges 
between 27 and 66% at I year (t t-14) in historical control 
patients. it has been consisantly found to be <2% in those 
who received the AICD l&21). 
The tr~swnous dttibriltetingeatheter. In this issue of the 
Journal. Wmkle and colleag~s (U) report on what certainly 
will become another milestone in :his rapidly evolving field. 
lo comparing the defibrillation efficacy of the conventional 
spring-patch electrode configuration with that of a single 
iotrava(cular defibrdlating catheter in patients undergoing 
AICD tmplantatioo. these investigators foand that perma- 
nent use of such a catheter would have been practical in 
almost 50% of their patients. Moreover, the defibrillating 
catheter dsplayed suitable pacing thresholds and sensing 
functions even after delivery of the countershock. 
The data of Wmkle et al. considerably extend the ficld of 
internal automatic delibrillation. The message is that implan- 
tation of the AICD mill not require a thoracotomy in a 
significant proportion of patients. Although current implan- 
tation techniques are associated with a relatively low inci- 
dence of major complications, the use of a oonthoracotomy 
approach could reduce the risk even further. A fully Mm- 
venous imolantation aooroach is also exoected to markedtv 
reduce the’cost of the-procedure. 
Althoueh the bioloeic feasibilitv and effectiveness of 
catheter defibrillation in humans was demonstrated by our 
group >I5 years ago (4.61. Winkle and his colleagues have 
successfully applied this technique in a setting directty aimed 
at neverdine sudden arrbvlbmic death. In their hands. the 
tranrvenousdefibdltating eatbetei has become ao integral 
pan of the automatic implantable cardiovener-defibrillator. 
idding a new dimension to the practical use of this new 
treatment. 
Irnptirations. If the history of artificial cardiac pacing is 
any guide. implantation of the automatic cardioverter- 
defibrillator will soon be transformed ioio a simple pad 
relatively noninvasive intervention. With further anticipated 
impmvements in defibrillating catheter technology, it is not 
unreasonable to expect that nonthoracotomy approaches 
wdl become routine implantation techniques. The clinical 
relevance of wch a development cannot be underestimated 
at a time when the AICD is being recognized as an essential 
modality in the management of survivors of arrhythmic 
cardiac arrest and of other patients suffering from malignant 
ventricular tachyarrhythmias. 
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